Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Share-based Compensation (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Share-based Compensation for 2 consecutive years, with -$15565.0 as the latest value for Q4 2023.

  • Quarterly Share-based Compensation fell 117.77% to -$15565.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $189244.0 through Dec 2023, down 56.3% year-over-year, with the annual reading at $6.0 for FY2025, 99.97% down from the prior year.
  • Share-based Compensation hit -$15565.0 in Q4 2023 for Bluejay Diagnostics, up from -$42482.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $219589.0 in Q1 2023 to a low of -$42482.0 in Q3 2023.